CD3-/CD19- vs CD3-/CD56+ Haplo NK for AML Pts Who Failed 1-2 Inductions

Status Terminated

Clinical Trial Summary

This is a phase II trial of related donor HLA-haploidentical NK-cell based therapy for the treatment of newly diagnosed acute myelogenous leukemia (AML) (except acute promyelocytic leukemia) in persons who failed to achieve a complete remission (CR) after one or two standard induction attempts. Failure is defined as ≥ 30% bone marrow blasts in a bone marrow of at least 20% cellularity at the mid-cycle (~day 14) bone marrow biopsy or residual AML on ~day 28 bone marrow biopsy by morphology, flow, PCR or FISH.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03290664
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact
Status	Terminated
Phase	Phase 2
Start date	October 18, 2017
Completion date	February 13, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01200355` - Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Phase 4
Active, not recruiting	`NCT03755414` - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation	Phase 1
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Active, not recruiting	`NCT04188678` - Resiliency in Older Adults Undergoing Bone Marrow Transplant	N/A
Completed	`NCT02543879` - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies	Phase 1
Completed	`NCT01681537` - Lenalidomide Plus Chemotherapy for AML	Phase 1
Completed	`NCT01385423` - Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)	Phase 1
Terminated	`NCT01193400` - Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years	Phase 2
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00981240` - Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes	Phase 1
Completed	`NCT00995332` - Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine	Phase 1/Phase 2
Completed	`NCT00726934` - The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients	N/A
Completed	`NCT00378534` - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants	Phase 2
Completed	`NCT01031498` - Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting	Phase 2
Completed	`NCT00789256` - Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	N/A
Completed	`NCT00098033` - Investigation of Clofarabine in Acute Leukemias	Phase 2
Completed	`NCT01020539` - Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia	Phase 1
Not yet recruiting	`NCT04709458` - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis	Phase 1
Recruiting	`NCT04024241` - Medium Dose of Cytarabine and Mitoxantrone
Terminated	`NCT02203773` - Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)	Phase 1